

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B17



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/16		A1	(11) International Publication Number: WO 95/28916 (43) International Publication Date: 2 November 1995 (02.11.95)
(21) International Application Number: PCT/US95/03825 (22) International Filing Date: 21 March 1995 (21.03.95) (30) Priority Data: 08/232,625 25 April 1994 (25.04.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/232,625 (CIP) Filed on 25 April 1994 (25.04.94) (71) Applicant (for all designated States except US): EDWARD MENDELL CO., INC. [US/US]; 2981 Route 2, Patterson, NY 12563-9970 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BAICHWAL, Anand, R. [IN/US]; 5 Kendell Drive, Wappingers Falls, NY 12590 (US). McCALL, Troy, W. [US/US]; 4 Sullivan Farm, New Milford, CT 06776 (US). (74) Agents: DAVIDSON, Clifford, M. et al.; Steinberg Raskin & Davidson, P.C., 21st floor, 1140 Avenue of the Americas, New York, NY 10036 (US).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published With international search report.
(54) Title: SUSTAINED RELEASE EXCIPIENT			
(57) Abstract A sustained-release excipient for use in oral solid dosage forms includes from about 15 to about 30 percent or more by weight heteropolysaccharide gum; an effective amount of a cationic cross-linking agent capable of cross-linking the heteropolysaccharide in an environment of use; and an inert pharmaceutical filler.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

SUSTAINED RELEASE EXCIPIENTFIELD OF THE INVENTION

5 The present invention relates to sustained release excipient formulations which may be blended with a wide range of therapeutically active medicaments and made into sustained release oral solid dosage forms.

BACKGROUND OF THE INVENTION

10 In our U.S. Patent Nos. 4,994,276; 5,128,143; and 5,135,757, hereby incorporated by reference, we reported that a controlled release excipient which is comprised of synergistic heterodisperse polysaccharides (e.g., a heteropolysaccharide such as xanthan gum in combination with a polysaccharide gum capable of cross-linking with the
15 heteropolysaccharide, such as locust bean gum) is capable of processing into oral solid dosage forms using either direct compression, following addition of drug and lubricant powder, conventional wet granulation, or a combination of the two. The release of the medicament from the formulations therein proceeded according to zero-order or
20 first-order mechanisms.

 The controlled release excipients disclosed in U.S. Patent Nos. 4,994,276, 5,128,143, and 5,135,757 are commercially available under the tradename TIMERx™ from
25 Edward Mendell Co., Inc., Patterson, N.Y., which is the assignee of the present invention.

 European Pat. No. 234670 B (Pankhania et al.) describes a sustained-release pharmaceutical formulation containing xanthan gum wherein the xanthan gum comprises
30 from about 7.5 to about 28 percent, by weight, of the formulation except for a formulation wherein the sustained release carrier comprises a mixture of 15-50 parts by weight dimethylsiloxane, 30-100 parts by weight silicic acid, 30-100 parts by weight mannans or galactans or a

-2-

mixture thereof, 50-150 parts by weight xanthans and 5-75 parts by weight micronized seaweed.

OBJECTS AND SUMMARY OF THE INVENTION

5 It is an object of the present invention to provide new sustained release matrices which, when incorporated into a final product, may cause the release of therapeutically active medicaments over an extended period of time when the dosage form is exposed to fluids in an environment
10 of use, e.g. from about 12 to about 24 hours or more.

 In accordance with the above-mentioned object, and others which will be apparent from the following disclosure, the present invention is related to sustained-release excipient for use in oral solid dosage forms,
15 comprising from about 15 to about 30 percent or more by weight heteropolysaccharide gum; an effective amount of a cationic cross-linking agent capable of cross-linking the heteropolysaccharide in an environment of use; and an inert pharmaceutical filler. In certain preferred embodiments,
20 the cationic cross-linking agent comprises from about 1 to about 20 percent by weight of the sustained-release matrix. In additional preferred embodiments, the inert pharmaceutical filler comprises from about 60 to about 85 percent by weight of the sustained-release matrix.

25 The sustained-release matrices of the present invention can be mixed with a wide range of therapeutically active medicaments and thereafter compressed into solid dosage forms such as tablets. The solid dosage forms thus made slowly release the medicament over about a 24-hour
30 time period when ingested and exposed to an environment of use, e.g. gastric fluids. By varying the amount of excipient relative to the medicament, a desired sustained-release profile can be attained.

 In preferred embodiments the heteropolysaccharide
35 comprises xanthan gum.

-3-

In another preferred embodiment the cationic cross-linking agent is calcium sulfate.

5 The present invention also provides a 24-hour sustained-release tablet for oral administration comprising (I) a hydrophilic material comprising (a) a heteropolysaccharide; or (b) a heteropolysaccharide and a cationic cross-linking agent capable of cross-linking said heteropolysaccharide; and (II) an inert pharmaceutical filler comprising from about 60 to about 85 percent by weight of
10 the hydrophilic material; and (III) an effective amount of a therapeutically active ingredient.

In addition, the present invention provides a method for providing a sustained release matrix for sustained release dosage forms containing one or more therapeutically
15 active medicaments, comprising preparing a sustained-release matrix by dry blending the requisite amounts of heteropolysaccharide gum, inert pharmaceutical filler, and cationic cross-linking agent. In certain preferred embodiments the sustained release excipient is prepared by
20 dry blending the requisite amounts of heteropolysaccharide gum, inert pharmaceutical filler, and cationic cross-linking agent, wet granulating the mixture, and then drying the mixture to obtain the final sustained release excipient. The sustained release excipient thereby obtained may
25 then be directly admixed with an active ingredient along with any further pharmaceutically necessary inert excipients, and then formulated into a final oral solid dosage form.

30 After admixture with the therapeutically active medicaments, the sustained release excipient/drug mixture may then be manufactured into a final dosage form, e.g., by directly compressing the mixture into tablets.

-4-

DETAILED DESCRIPTION OF THE INVENTION

5 The excipients of the present invention have been pre-
optimized by providing a sustained-release excipient pro-
duct which may be mixed with a wide range of medicaments
and made into oral solid dosage forms capable of releasing
the active medicament in the environment of use over about
a 12 to 24 hour time period, without the aid of the usual
pharmaceutical dry or wet binders, fillers, disintegrants,
glidants etc., which must be added in many prior art compo-
10 sitions to obtain an acceptable solid dosage form. Thus,
the excipients of the present invention substantially over-
come the need for conducting further experimentation needed
to optimize release characteristics and tabletting prop-
erties for a particular therapeutically active medicament.

15 In other words, the controlled release excipient used
in the present invention provides a product which contains
a combination of ingredients in preselected proportions to
each other which provides a desired controlled release
profile over a 12 to at least a 24-hour period for a wide
20 variety of drugs. Thus, once the excipient product is
admixed with an active medicament (and preferably with a
lubricant) in a ratio to the sustained-release excipient in
accordance with the present invention, the resulting mix-
ture may be made into oral solid dosage forms capable of
25 releasing an active medicament over an extended period of
time.

Xanthan gum, the preferred heteropolysaccharide, is
produced by microorganisms, for instance, by fermentation
with the organism *xanthomonas compestris*. Most preferred
30 is xanthan gum which is a high molecular weight ($>10^6$)
heteropolysaccharide. Xanthan gum contains D-glucose,
D-mannose, D-glucuronate in the molar ratio of 2.8:2.0:20,
and is partially acetylated with about 4.7% acetyl. Xanthan
gum also includes about 3% pyruvate, which is attached to
35 a single unit D-glucopyromosyl side chain as a metal. It

-5-

dissolves in hot or cold water and the viscosity of aqueous solutions of xanthan gum is only slightly affected by changes in the pH of a solution between 1 and 11.

5 The term "heteropolysaccharide" as used in the present invention is defined as a water-soluble polysaccharide containing two or more kinds of sugar units, the heteropolysaccharide having a branched or helical configuration, and having excellent water-wicking properties and immense thickening properties. When admixed with an appropriate
10 cationic cross-linking agent capable of cross-linking with the heteropolysaccharide in accordance with the present invention and exposed to an aqueous solution, gastric fluid, etc., the gum packs closely and many intermolecular attachments are formed which make the structure strong and
15 provide a hydrophilic gum matrix having high gel strength. The cationic cross-linking agent is therefore an agent capable of cross-linking the heteropolysaccharide, thus affecting the rate of release of the active medicament.

The cationic cross-linking agent may be monovalent or
20 multivalent metal cations. The preferred salts are the inorganic salts, including various alkali metal and/or alkaline earth metal sulfates, chlorides, borates, bromides, citrates, acetates, lactates, etc. Specific examples of suitable cationic cross-linking agents include calcium
25 sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate
30 and sodium fluoride or mixtures thereof. Multivalent metal cations may also be utilized. However, the preferred cationic cross-linking agents are bivalent. Particularly preferred salts are calcium sulfate and sodium chloride. The cationic cross-linking agents of the present invention are
35 added in an amount effective to obtain a desirable in-

-6-

creased gel strength due to the cross-linking of the gelling agent (e.g., the heteropolysaccharide and homopolysaccharide gums).

Two steps which are generally required for gelation are the fast hydration of the macromolecules which comprise the hydrophilic material and thereafter the association of the molecules to form gels. Thus, two important properties of a hydrophilic gel matrix which are needed for application in a sustained-release system are the fast hydration of the system and a matrix having a high gel strength. As noted above, the cationic cross-linking agent may affect the hydration process of the heteropolysaccharide. These two important properties which are needed for application in a sustained-release system are the fast hydration of the system and a matrix having a high gel strength. These two important properties which are necessary to achieve a slow release hydrophilic matrix are maximized in the present invention by the particular combination of materials. In particular, heteropolysaccharides such as xanthan gum have excellent water wicking properties which provide fast hydration. On the other hand, the combination of xanthan gum with cationic cross-linking materials and the like which are capable of cross-linking the rigid helical ordered structure of the xanthan gum and can alter the gelation process and thus effect the rate of release of the active medicament.

In the present invention, it has been discovered that the controlled release properties of the tablets are optimized when the ratio of xanthan gum to cationic cross-linking agent (e.g., calcium sulfate, etc.) is from about 1:1 to about 3.5:1 and most preferably from about 1.5:1 to about 3:1, although xanthan gum in an amount of from about 15 to about 30 percent or more by weight of the sustained release excipient provides an acceptable slow release product.

-7-

In one preferred embodiment, the cationic cross-linking agent comprises calcium sulfate, and is present in the sustained release excipient in an amount of about 10 percent, by weight of the excipient. The ratio of the heteropolysaccharide to the cationic cross-linking agent is preferably from about 1.5:1 to about 3:1.

Any generally accepted soluble or insoluble inert pharmaceutical filler (diluent) material can be used. Preferably, the inert pharmaceutical filler comprises a monosaccharide, a disaccharide, a polyhydric alcohol, a cellulose (such as microcrystalline cellulose) and/or mixtures thereof. Examples of suitable inert pharmaceutical fillers include sucrose, dextrose, lactose, microcrystalline cellulose, xylitol, fructose, sorbitol, starches, mixtures thereof and the like. However, it is preferred that a soluble pharmaceutical filler such as dextrose, sucrose, or mixtures thereof be used.

In certain preferred embodiments of the invention, the sustained release matrix further comprises a hydrophobic material in an amount effective to slow the hydration of the gum without disrupting the hydrophilic matrix formed by the heteropolysaccharide when the formulation is exposed to fluids in an environment of use. This may be accomplished by granulating the sustained release matrix with a solution or dispersion of hydrophobic material prior to the incorporation of the medicament. The hydrophobic material may be selected from ethylcellulose, acrylic and/or methacrylic acid polymers or copolymers, hydrogenated vegetable oils, zein, as well as other pharmaceutically acceptable hydrophobic materials known to those skilled in the art. Other hydrophobic cellulosic materials such as other alkyl celluloses may also be used. The amount of hydrophobic material incorporated into the sustained release matrix is that which is effective to slow the hydration of the gums without disrupting the hydrophilic matrix formed upon exposure

-8-

to an environmental fluid. In certain preferred embodiments of the present invention, the hydrophobic material may be included in the sustained release matrix in an amount from about 1% to about 20% by weight. More preferably, the hydrophobic material may be included in the sustained release matrix in an amount from about 3% to about 12%, and most preferably from about 5% to about 10%, by weight of the final formulation. The hydrophobic material may be dissolved in an organic solvent or dispersed in an aqueous solution for incorporation into the formulation.

The combination of the hydrophilic material (e.g., xanthan gum) with the cationic cross-linking agent and inert diluent provides a ready to use sustained-release excipient in which a formulator need only blend the desired active medicament and an optional lubricant with the excipient and then make an oral solid dosage form. The sustained-release excipient may thus comprise a physical admix of the heteropolysaccharide along with a cationic cross-linking agent, or soluble excipient such as sucrose, lactose or dextrose.

One of the limitations of direct compression as a method of tablet manufacture is the size of the tablet. For example, where the dosage form is an oral sustained release tablet and the dose of therapeutically active agent to be contained in the tablet is relatively large, a pharmaceutical formulator may choose to wet granulate the drug with other excipients to attain a desired tablet size with the correct compact strength (e.g., hardness). Usually the amount of filler/binder or excipients needed in wet granulation is less than that in direct compression since the process of wet granulation contributes to some extent toward the desired physical properties of a tablet. Accordingly, the sustained release pharmaceutical excipient prepared in accordance with the present invention may be subjected to wet granulation before the medicament is

-9-

added. In this technique, the desired amounts of the heteropolysaccharide, the cationic cross-linking agent, and the inert filler are mixed together and thereafter a moistening agent such as water, propylene glycol, glycerol, alcohol or the like is added to prepare a moistened mass. Next, the moistened mass is dried. The dried mass is then milled with conventional equipment into granules. Therefore, the sustained-release excipient product is ready to use. The granulate thus obtained has certain advantages including the fact that it is free-flowing, has good cohesive properties, and can be admixed with an active agent (e.g., drug) and can be directly compressed into tablets. On the other hand, the granulate can be formulated into a capsule, used in the granulate form, extruded, and/or spheronized with an active medicament to form pellets, etc.

Alternatively, it is possible to dry mix the ingredients of the sustained release excipient without utilizing a wet granulation step. This procedure may be utilized, for example, where a wet granulation step is to be accomplished when the active ingredient is directly added to the ingredients of the sustained release excipient. On the other hand, this procedure may also be used where no wet granulation step whatsoever is contemplated. If the mixture is to be manufactured without a wet granulation step, and the final mixture is to be tableted, it is preferred that all or part of the inert diluent comprise a pre-manufactured direct compression diluent. Such direct compression diluents are widely used in the pharmaceutical arts, and may be obtained from a wide variety of commercial sources. Examples of such pre-manufactured direct compression excipients include Emcocel® (microcrystalline cellulose, N.F.), Emdex® (dextrates, N.F.), and Tab-Fine® (a number of direct-compression sugars including sucrose, fructose, and dextrose), all of which are commercially available from Edward Mendell Co., Inc., Patterson, New

-10-

York). Other direct compression diluents include Anhydrous lactose (Lactose N.F., anhydrous direct tableting) from Sheffield Chemical, Union, N.J. 07083; Elcems® G-250 (Powdered cellulose, N.F.) from Degussa, D-600 Frankfurt (Main) Germany; Fast-Flo Lactose® (Lactose, N.F., spray dried) from Foremost Whey Products, Banaboo, WI 53913; Maltrin® (Agglomerated maltrodextrin) from Grain Processing Corp., Muscatine, IA 52761; Neosorb 60® (Sorbitol, N.F., direct-compression) from Roquette Corp., 645 5th Ave., New York, NY 10022; Nu-Tab® (Compressible sugar, N.F.) from Ingredient Technology, Inc., Pennsauken, NJ 08110; Polyplasdone XL® (Crospovidone, N.F., cross-linked polyvinylpyrrolidone) from GAF Corp., New York, NY 10020; Primojel (Sodium starch glycolate, N.F., carboxymethyl starch) from Generichem Corp., Little Falls, NJ 07424; Solka Floc (Cellulose floc) from Edward Mendell Co., Carmel, NY 10512; Spray-dried lactose® (Lactose N.F., spray dried) from Foremost Whey Products, Baraboo, WI 53913 and DMV Corp., Vehgel, Holland; and Sta-Rx 1500® (Starch 1500) (Pregelatinized starch, N.F., compressible) from Colorcon, Inc., West Point, PA 19486.

In general, the formulator may prepare a directly compressible diluent, by wet granulating or spray drying lactose, for example. For purposes of the present invention, these specially treated inert diluents will be referred to as "directly compressible" inert diluents.

In further embodiments of the present invention, the directly compressible inert diluent which is used in conjunction with the sustained release pharmaceutical excipient of the present invention is an augmented microcrystalline cellulose as disclosed in U.S. Patent Application Serial No. 08/370,576, filed January 9, 1995, and entitled "PHARMACEUTICAL EXCIPIENT HAVING IMPROVED COMPRESSIBILITY", inventors J. Staniforth, B. Sherwood and E. Hunter.

-11-

Once the sustained release excipient of the present invention has been prepared, it is then possible to blend the same with an active medicament, metoprolol, e.g., in a V-blender. The mixture may then be manufactured into the
5 desired final dosage form. If desired, the mixture can be directly compressed into tablets, or subjected to other intermediate processing steps such as wet granulation.

The dosage forms of the present invention are preferably tablets. However, the ingredients may also be
10 formulated in a capsule, extruded and spheronized with an active medicament to form pellets, etc.

For example, the complete mixture, in an amount sufficient to make a uniform batch of tablets, is then subjected to tableting in a conventional production scale
15 tableting machine at normal compression pressure, i.e. about 2000-1600 lbs/sq in. However, the mixture should not be compressed to such a degree that there is subsequent difficulty in its hydration when exposed to gastric fluid. An effective amount of any generally accepted pharmaceu-
20 tical lubricant, including the calcium or magnesium soaps may be added to the above-mentioned ingredients of the excipient be added at the time the medicament is added, or in any event prior to compression into a said dosage form. One preferred lubricant is Pruv®, e.g., in the amount of
25 about 3.0 percent of the solid dosage form.

The average tablet size for round tablets is preferably about 500 mg to 750 mg and for capsule-shaped tablets about 750 mg to 1000 mg.

The average particle size of the granulated excipient
30 of the present invention ranges from about 50 microns to about 400 microns and preferably from about 185 microns to about 265 microns. The particle size of the granulation is not narrowly critical, the important parameter being that the average particle size of the granules, must permit the
35 formation of a directly compressible excipient which forms

-12-

pharmaceutically acceptable tablets. The desired tap and bulk densities of the granulation of the present invention are normally between from about 0.3 to about 0.8 g/ml, with an average density of from about 0.5 to about 0.7 g/ml. For best results, the tablets formed from the granulations of the present invention are from about 6 to about 8 kg hardness. The average flow of the granulations prepared in accordance with the present invention are from about 25 to about 40 g/sec.

Variables which may affect the release rate and the compressibility of tablets prepared with the excipient of the present invention are the drug to gum ratio; the method of incorporation of excipient (method of granulation); the relative amount of the gum to cationic cross-linking agent; and the ratio of active medicament to the sustained-release excipient.

The sustained release excipient formulations of the present invention may be utilized in the preparation of a wide range of 24 hour solid dosage forms which include a wide range of water-soluble or water-insoluble medicaments. Examples of such therapeutically active agents include antihistamines (e.g., dimenhydrinate, diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate), analgesics (e.g., aspirin, codeine, morphine, dihydromorphone, oxycodone, etc.), anti-inflammatory agents (e.g., naproxen, diclofenac, indomethacin, ibuprofen, aspirin, sulindac), acetaminophen, gastro-intestinals and anti-emetics (e.g., metoclopramide), anti-epileptics (e.g., phenytoin, meprobamate and nitrezepam), vasodilators (e.g., nifedipine, papaverine, diltiazem and nocardipine), anti-tussive agents and expectorants (e.g., codeine phosphate), anti-asthmatics (e.g. theophylline), anti-spasmodics (e.g., atropine, scopolamine), hormones (e.g., insulin, heparin), diuretics (e.g., ethacrynic acid, bendroflumethiazide), anti-hypotensives (e.g., propranolol, clonidine), bronchodilators

-13-

(e.g., albuterol), anti-inflammatory steroids (e.g., hydrocortisone, triamcinolone, prednisone), antibiotics (e.g., tetracycline), antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, antacids, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine). The above list is not meant to be exclusive.

Upon oral ingestion and contact with gastric fluid, the controlled release tablets prepared according to the present invention swell and gel to form a hydrophilic gel matrix from which the drug is released. The swelling of the matrix causes a reduction in the bulk density of the tablet and provides the buoyancy necessary to allow the gel mass to float on the stomach contents to provide a slow delivery of the medicament. The matrix, the size of which is dependent upon the size of the original tablet, can swell considerably and become obstructed near the opening to the pylorus. Since the medicament is dispersed throughout the tablet (and consequently throughout the gel matrix), a constant amount of drug can be released per unit time in vivo by dispersion or erosion of the outer portions of the matrix. This phenomenon is commonly referred to as a zero order release profile or zero order kinetics. The process continues, with the matrix remaining buoyant in the stomach, until substantially all of the medicament is released. The chemistry of certain of the ingredients comprising the excipients of the present invention such as xanthan gum is such that the excipients are considered to be self-buffering agents which are substantially insensitive to the solubility of the medicament and likewise insensitive to the pH changes along the length of the gastrointestinal tract. Moreover, the chemistry of the ingredients comprising the excipients of the present invention is believed to be similar to certain known mucoadhesive substances such as polycarbophil. Mucoadhesive properties are

-14-

desirable for buccal delivery systems. Thus, it may be possible that the gel system could potentially loosely interact with the mucin in the gastrointestinal tract and thereby provide another mode by which a constant rate of delivery of the medicament is achieved. The above hypothesis is included for discussion purposes only and is not intended to limit the scope of the present invention.

These two phenomena, i.e., buoyancy of the gel matrix and the mucoadhesive properties discussed above, are possible mechanisms by which the gel matrix of the present invention could interact with the mucin and fluids of the gastrointestinal tract and provide a constant rate of delivery of the medicament. Other mechanisms are possible and therefore this hypothesis is not meant to limit the scope of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

EXAMPLES 1-3

The sustained release excipient is prepared by dry blending the requisite amounts of xanthan gum, dextrose and calcium sulfate in a high-speed mixer/granulator for 2 minutes. While running choppers/impellers, the water is added and the mixture is granulated for another 2 minutes. The granulation is then dried in a fluid bed dryer to a loss on drying weight (LOD) of between 4 and 7%. The granulation is then milled using 20 mesh screens. The ingredients of the sustained release excipient of Example 1 are set forth in Table 1 below:

-15-

TABLE 1PREPARATION OF SUSTAINED RELEASE EXCIPIENT

	<u>Component</u>	<u>%-Ex. 1</u>	<u>%-Ex. 2</u>	<u>%-Ex. 3</u>
5	1. Xanthan gum	30	15	30
	2. Dextrose	60	75	70
	3. Calcium Sulfate	10	10	0
	4. Water	10*	10*	10*
10	*removed during processing			

Next, the sustained release excipient prepared as detailed above is dry blended with a desired amount of medicament (in the following examples metoprolol, provided as the tartrate salt) in a V-blender for 10 minutes. A suitable amount of tabletting lubricant Pruv® (sodium stearyl fumarate, NF, commercially available from the Edward Mendell Co., Inc.) for the following examples is added and the mixture is blended for another 5 minutes. This final mixture is compressed into tablets, each tablet containing 100 mg metoprolol. The tablets of Example 1 weighed 618.5 mg. The tablets of Example 2 weighed 618.5 mg. The tablets of Example 3 weighed 618.5 mg. The drug:gum ratio of the tablets of Example 1 was 1:1.5. The drug:gum ratio of the tablets of Example 2 was 1:0.75. The drug:gum ratio of the tablets of Example 3 was 1:1.5. The ingredients of the tablets of Examples 1-3 are set forth in Table 2 below:

TABLE 2

	<u>Component</u>	<u>%</u>
30	1. Sustained Release Excipient	80.8%
	2. Metoprolol	16.2%
	3. Pruv®	3.0%

Dissolution tests were then carried out on the tablets of Examples 1-3. The dissolution tests are conducted in an automated USP dissolution apparatus (Paddle Type II, pH 6.8 buffer, 100 rpm.). The results are set forth in Table 3 below:

-16-

TABLE 3Effect of Single Gum Composition

5	<u>Time(hours)</u>	<u>Example 1</u>	<u>Example 2</u>	<u>Example 3</u>
	0	0.0	0.0	0.0
	2	25.3	29.0	20.7
	4	37.9	42.7	32.3
	8	56.3	63.6	50.2
10	12	70.6	77.9	64.1
	16	81.3	88.2	74.3
	20	89.0	94.9	81.3
	24	97.6	98.8	—

From the results provided in Table 3, it can be seen that formulations made with a greater concentration of gum produced slower drug release rates. It is also evident that the incorporation of calcium sulfate into single gum systems results in a faster drug release rates compared to formulations without calcium sulfate. Accordingly, the results provide that the tablets in Example 1 are suitable for delivering medicaments as an oral solid dosage form over a 24-hour oral period of time.

The examples provided above are not meant to be exclusive. Many other variations of the present invention would be obvious to those skilled in the art, and are contemplated to be within the scope of the appended claims.

-17-

WHAT IS CLAIMED IS:

1. A sustained release pharmaceutical excipient for oral solid dosage forms, comprising:

5 a heteropolysaccharide gum, the percentage of said heteropolysaccharide gum from about 10 to about 40 percent of the sustained release excipient,

10 a cationic cross-linking agent capable of cross-linking said heteropolysaccharide gum in the presence of aqueous solutions, the ratio of said heteropolysaccharide gum to said cationic cross-linking agent being from about 1:1 to about 3.5:1;

15 an inert pharmaceutical diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, a cellulose, a starch, and mixtures thereof, the percentage of said inert diluent being from about 60 to about 85 percent by weight, of the sustained release excipient.

20 2. The sustained release excipient of claim 1, wherein said inert pharmaceutical diluent is selected from the group consisting of lactose, dextrose, sucrose, fructose, microcrystalline cellulose, xylitol, sorbitol and mixtures thereof.

25 3. The sustained release excipient of claim 1, wherein the ratio of said inert pharmaceutical diluent to said heteropolysaccharide gum is from about 6:1 to about 2:1.

30 4. The sustained release excipient of claim 1, wherein said cationic cross-linking agent comprises from about 1 to about 20 percent of said sustained release excipient, by weight.

-18-

5. The sustained release excipient of claim 1, wherein said cationic cross-linking agent is selected from the group consisting of calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, sodium fluoride and mixtures thereof.

10

6. The sustained release excipient of claim 1, wherein said cationic cross-linking agent is calcium sulfate.

15

7. The sustained release excipient of claim 1, wherein said heteropolysaccharide gum is xanthan gum.

20

8. The sustained release excipient of claim 1, wherein said excipient is in the form of a granulate.

9. The sustained release excipient of claim 1, wherein said inert pharmaceutical diluent is in a directly compressible form.

25

10. The sustained release excipient of claim 1, wherein said heteropolysaccharide gum, said inert pharmaceutical diluent, and said cationic cross-linking agent are granulated with a hydrophobic material selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zein, hydrogenated vegetable oils, and mixtures of any of the foregoing, said hydrophobic material being included in an amount effective to slow the hydration of said gelling agent when exposed to an environmental fluid.

30

-19-

11. The sustained release excipient of claim 10, wherein said hydrophobic material is ethylcellulose.

12. A granulate useful as a sustained release pharmaceutical excipient for oral solid dosage forms, comprising:

a heteropolysaccharide gum, the percentage of said heteropolysaccharide gum from about 10 to about 40 percent of the sustained release excipient,

a cationic cross-linking agent capable of cross-linking said heteropolysaccharide gum in the presence of aqueous solutions, the ratio of said heteropolysaccharide gum to said cationic cross-linking agent being from about 1:1 to about 3.5:1;

an inert pharmaceutical diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, a cellulose, a starch, and mixtures thereof, the percentage of said inert diluent being from about 60 to about 85 percent by weight, of the sustained release excipient;

said heteropolysaccharide gum, cationic cross-linking agent, and said inert pharmaceutical diluent having been agglomerated into granular particles via a wet granulation method.

13. The granulate of claim 12, wherein said inert pharmaceutical diluent is selected from the group consisting of lactose, dextrose, sucrose, fructose, microcrystalline cellulose, xylitol, sorbitol and mixtures thereof.

14. The granulate of claim 12, wherein the ratio of said inert pharmaceutical diluent to said heteropolysaccharide gum is from about 6:1 to about 2:1.

-20-

15. The granulate of claim 12, wherein said cationic cross-linking agent comprises from about 1 to about 20 percent of said sustained release excipient, by weight.

5 16. The granulate of claim 12, wherein said cationic cross-linking agent is selected from the group consisting of calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride,
10 sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, sodium fluoride and mixtures thereof.

15 17. The granulate of claim 12, wherein said cationic cross-linking agent is calcium sulfate.

18. The granulate of claim 12, wherein said heteropolysaccharide gum is xanthan gum.

20 19. A method for preparing a sustained release excipient, comprising:

 wet granulating a heteropolysaccharide gum, a cationic cross-linking agent capable of cross-linking said heteropolysaccharide gum in the presence of aqueous solu-
25 tions, and an inert pharmaceutical diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, a cellulose, a starch, and mixtures thereof, and

 drying the mixture to obtain distinct excipient
30 particles.

-21-

20. The method of claim 19, wherein the percentage of said heteropolysaccharide gum is from about 10 to about 40 percent of the granulate, the percentage of said inert diluent is from about 60 to about 85 percent by weight of the granulation, and the ratio of said heteropolysaccharide gum to said cationic cross-linking agent is from about 1:1 to about 3.5:1.

21. The method of claim 20, wherein said heteropolysaccharide gum is xanthan gum and said cationic cross-linking agent is calcium sulfate.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03825

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/16

US CL : 424/468, 485, 500

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/468, 485, 500

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,795,642 (COHEN ET AL.) 03 January 1989, see particularly column 5, lines 15-34 and column 3, lines 44-52.	1-7
Y	US, A, 4,303,691 (SAND ET AL.) 01 December 1981, see particularly column 9, lines 63-66.	1-7
Y	US, A, 5,169,639 (BAICHWAL ET AL.) 08 December 1992, see particularly column 6, lines 47-52.	1-7

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

- * Special categories of cited documents:
- *A* document defining the general state of the art which is not considered to be part of particular relevance
- *E* earlier document published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

05 MAY 1995

Date of mailing of the international search report

19 JUN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

AMY HULINA

Telephone No. (703) 308-2351